Cancer News: Myeloma
Multiple myeloma treatment expected to be approved in Europe
European regulators have adopted a positive opinion for ixazomib capsules combined with lenalidomide and dexamethasone for the treatment of multiple myeloma.
The effects of weight on multiple myeloma
Researchers discovered that the patient’s body mass index is contributing to multiple myeloma growth and progression.
EU regulator extends carfilzomib’s approval for multiple myeloma
EU regulator approved carfilzomib with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
Daratumumab demonstrates efficacy against multiple myeloma
Adding daratumumab to a standard two-drug regimen reduced the risk of cancer progression in patients with recurrent or refractory multiple myeloma.
New drug for multiple myeloma closer to EU conditional approval
European regulators have recommended conditional approval for daratumumab, an immunotherapy treatment for multiple myeloma.
New therapeutic approach shows promise against multiple myeloma
A new immunotherapy-related therapeutic approach against multiple myeloma induced record-level clinical results, researchers reveal.
Carfilzomib promising for multiple myeloma
Adding carfilzomib to the treatment of relapsed and/or refractory multiple myeloma with bortezomib and lenalidomide induced positive results, a new study shows.
Multiple myeloma: improved patient outcomes with combo therapy
Multiple myeloma patients treated with daratumumab combined with standard chemotherapy lived longer without disease progression, a new study finds.
Ixazomib promising for treatment-resistant multiple myeloma
Clinical results reveal the effectiveness of ixazomib plus lenalidomide and dexamethasone in treating patients with relapsed and/or refractory multiple myeloma.
Carfilzomib increased survival rate in relapsed multiple myeloma
Relapsed multiple myeloma patients treated with carfilzomib plus dexamethasone instead of bortezomib plus dexamethasone lived twice as long without disease progression.
Elotuzumab (Empliciti) gets FDA approval for myeloma
The monoclonal antibody, Elotuzumab, received FDA’s approval to be used for the treatment of myeloma in combination with lenalidomide (Revlimid) and dexamethasone.
Immuno-oncology treatment for multiple myeloma gets US approval
The FDA approved the immuno-oncology treatment, Empliciti, for the treatment of patients with multiple myeloma.
EU approves combination therapy for relapsed multiple myeloma
European regulators approved carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma.
New oral treatment approved for myeloma
Takeda’s oral myeloma treatment, ixazomib (Ninlaro), got approved by the FDA as a second-line combination therapy.
Immunotherapy gets U.S. approval for advanced multiple myeloma
The FDA approved Johnson & Johnson’s immunotherapy drug, Darzalex (daratumumab) for the treatment of patients with advanced multiple myeloma.
Immunotherapy shows promise against drug-resistant multiple myeloma
Daratumumab, a breakthrough antibody therapy, showed very promising results in drug-resistant patients with multiple myeloma whose disease had relapsed.
One step closer to a new drug for multiple myeloma in Europe
European regulators have accepted the marketing authorization application for ixazomib, an investigational oral drug meant to treat relapsed/refractory myeloma patients.
Myeloma: the hope lies in the mutated genes
Researchers have discovered a method to identify which myeloma patients are at a greater risk of relapse and premature death.
One step closer to a new multiple myeloma drug in EU
European regulators have granted an accelerated assessment to Takeda’s ixazomib, a new drug for relapsed and/or refractory multiple myeloma.
Elotuzumab plus standard treatment benefited multiple myeloma patients
Adding elotuzumab to standard treatment benefited patients with relapsed and refractory myeloma as it improved progression-free survival rates, a new study reveals.
New antibody brings hope to patients with relapsed multiple myeloma
Adding the innovative immunotherapy elotuzumab to standard treatment extended the duration of remissions by about five months in patients with relapsed multiple myeloma.
New blood cancer drug gets FDA approval
Novartis multiple myeloma drug, Farydak received FDA’s approval, in spite of advisory panel’s negative opinion.
Important FDA drug approval for multiple myeloma patients
Revlimid, already approved as a treatment for previously treated patients of multiple myeloma, will be available for newly diagnosed patients as well.
Multiple myeloma treatment with 3 drugs shows unprecedented benefit
Investigators have produced significantly improved results for treating multiple myeloma by adding a 3rd drug to the accepted 2-drug combination in a trial.
Multiple myeloma drug approved for re-treatment in the US
The US FDA approved bortezomib for the re-treatment of multiple myeloma adult patients who relapsed at least six months after responding to bortezomib therapy.
New strategies for relapsed/refractory multiple myeloma explored
Newer targeted therapies and genomic analysis are moving the management of relapsed/refractory multiple myeloma forward.
Novartis bone marrow cancer drug meets goal in late-stage study
An experimental drug from Novartis to treat a type of bone marrow cancer met its primary goal in a late-stage study, the Swiss drugmaker said.
Combo treatment: new standard for multiple myeloma?
A continuous, combined treatment of multiple myeloma outperformed standard care in older patients or those not eligible for stem cell transplant, according to a researcher at the annual meeting of the American Society of Hematology.
High response rates seen with oral Takeda myeloma drug: study
Most newly diagnosed multiple myeloma patients had a very strong response to an experimental oral drug, when given in combination with standard treatments, according to a trial.
Revlimid slows multiple myeloma relapse
Multiple myeloma patients in remission after initial therapy can prolong the time to relapse through lenalidomide (Revlimid) maintenance treatment (an immune modulator).